Precipio Inc (PRPO)
NASDAQ:PRPO
Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$23.09
$0.30(5.08%)
At close: 4:00 PM EST
$23.09
$0.30(5.08%)
Day’s Range― - ―
52-Week Range$5.21 - $29.80
Previous CloseN/A
Volume11.00
Average Volume (3M)19.92K
Market Cap
$52.60M
Enterprise Value$49.34M
Total Cash (Recent Filing)$6.04M
Total Debt (Recent Filing)$3.65M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding1,783,682
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda33.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth (30% YoY In 2025)A 30% revenue increase to $24M in 2025 indicates durable demand expansion for core diagnostic services. Consistent top-line growth supports scale benefits, raises operating leverage potential, and provides a firmer base to invest in commercial expansion and product commercialization over the next 2–5 years.
Positive Operating And Free Cash FlowTransition to positive operating and free cash flow reduces refinancing risk and funds reinvestment without dilutive financing. Improved cash generation and paydown of a legacy loan increase financial flexibility, enabling scaling of commercial efforts and product buildout with less reliance on external capital.
Pathology Services: Under‑utilized Capacity And Operational LeverageUnder‑utilized lab capacity implies high incremental margins as volumes grow, creating durable operating leverage in the services business. This structural scalability supports sustained cash conversion and funds cross-selling of higher‑value productized services, enhancing long‑term profitability as volume scales.
Bears Say
Earnings‑quality & Reporting Transparency ConcernsZeroed gross/operating profit fields and declining total assets reduce confidence in financial statement continuity and comparability. Persistent negative ROE and past asset erosion complicate assessment of sustainable profitability, increasing the risk that reported improvements may mask accounting or timing distortions.
Products Margin Volatility And Execution RiskLarge, one‑off margin swings tied to inventory prebuilds show product economics are highly volume- and timing-sensitive. If high‑margin production runs are not repeatable with steady demand, profitability will remain unpredictable and product scaling may fail to deliver the durable margin uplift management projects.
Customer Onboarding And Operational Dependence Slow Product RampLengthy validation, IT integration and customer lab disruptions create sustained delays to revenue recognition and limit predictable product adoption. Dependence on customers' operational readiness makes growth lumpy and increases sales cycle length, constraining the pace at which product revenues can reliably scale.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $5.21 and its highest was $29.80 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $52.60M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is May 20, 2026 which is in 33 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Apr 06, 2026. The company reported $0.295 earnings per share for the quarter, beating the consensus estimate of N/A by $0.295.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,783,682 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of $0.295 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.283%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
-2.78%
Trailing 12-Months
Asset Growth
25.42%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
PRPO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a generally positive trajectory: the company reached a key inflection to positive cash flow, delivered 30% revenue growth to $24M, improved overall gross margin from 41% to 45%, strengthened the commercial organization, and demonstrated product manufacturing scalability and clinical validation. Key challenges remain in the Products division—revenue growth was muted by customer operational interruptions, earlier under-resourced commercial coverage, onboarding timing and margin volatility driven by one-time production effects. Management presented concrete mitigations (new hires, backup lab arrangements, distributor strategy) and a clear growth focus for 2026, so the balance of developments is favorable but with identifiable execution risks to monitor.View all PRPO earnings summariesTechnical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
11.21% Insiders
1.73% Mutual Funds
3.40% Other Institutional Investors
82.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---